Liquidia Corp(US:LQDA) Globenewswire·2025-11-03 13:00Core Insights - Liquidia Corporation is focused on revolutionizing care for patients with respiratory and vascular diseases through innovative therapies and proprietary technology [2] Company Updates - Liquidia's executive leadership team will provide business updates during fireside chats at two investor conferences in November [1] - The conferences include the 2025 UBS Global Healthcare Conference on November 10 and the Jefferies London Healthcare Conference on November 18 [3] Product Information - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The company is developing L606, a sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [2] - Liquidia also markets generic Treprostinil Injection for the treatment of PAH [2]